Assessing asthma management for patients in Hong Kong
To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong
Chinese University of Hong Kong · NCT04639791
This study is looking at how well asthma is managed in patients in Hong Kong who are on advanced treatments to see if they are doing better and to help doctors learn more about these therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong (other) |
| Drugs / interventions | omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab |
| Locations | 1 site (Shatin) |
| Trial ID | NCT04639791 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the control and management of asthma patients in Hong Kong who are receiving step 4 and 5 treatment according to the Global Initiative for Asthma (GINA) guidelines. Over a two-year period, the study will monitor these patients for exacerbations and assess those on biologic therapies for their suitability and outcomes. The goal is to generate local data that can inform healthcare planning for severe asthma and to establish a biologic registry to enhance local physicians' experience with these advanced treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are on GINA step 4 or 5 asthma treatment.
Not a fit: Patients with other significant respiratory diseases or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management and outcomes for patients with difficult-to-treat and severe asthma.
How similar studies have performed: While there have been studies on asthma management, this specific approach focusing on severe asthma in Hong Kong is novel and aims to fill a local data gap.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Asthma patients with age ≥18. Asthma is defined as those with a consistent history and prior documented evidence of variable airflow obstruction. * Subjects on steps 4 and 5 of GINA asthma therapy Exclusion Criteria: * Patients with respiratory diseases with other known respiratory diseases including chronic obstructive pulmonary disease, bronchiectasis, tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer * Individuals older than 40 years with a smoking history of more than 10 pack-years * Pregnant women
Where this trial is running
Shatin
- Prince of Wales Hospital — Shatin, Hong Kong (RECRUITING)
Study contacts
- Study coordinator: Fanny WS Ko, MD
- Email: fannyko@cuhk.edu.hk
- Phone: 85235053133
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Asthma